Nucana presents encouraging data on nuc-3373 in colorectal cancer at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics 2023

Nuc-3373 demonstrates promising anti-tumor activity and a favorable safety profile as part of nufiri-bevacizumab and nufox-bevacizumab in second-line colorectal cancer patients

NCNA Ratings Summary

NCNA Quant Ranking